Genetic,Immunologic and Biotransformation Studies of Patients on Procainamide

Abstract

This report represents follow-up observations of a unique long-term study of patients on procainamide (PA) for various cardiac arrhythmias. Serologic and clinical evaluations associated with drug-related autoimmunity were assessed and patients were characterized for factors postulated to influence susceptibility to autoimmunity, including acetylator phenotype, oxidative metabolism of PA, HLA class profile, and production of interleukin-1 (IL-1) and tumor necrosis factor (TNF). Fifty-two percent had IgM and 70% IgG antibodies to total histones; 67% had IgG antibodies to histone H2A/H2B. Patients were equally divided between fast and slow acetylators. N-oxidative metabolism of PA was indicated by the presence of urinary nitroprocainamide, which correlated with elevated titers of antihistone antibodies. There was a significant incidence of the DQw7 split of DQw3 in PA patients when compared to controls, and the frequency of antibodies to total histones and H2A/H2B was significantly increased in the DQw7 patients. C4A*QO and C4B*QO alleles were more frequent in the PA patients than in controls. IL-1 and TNF production was not different in patients compared to controls. These data suggest that certain genetic factors may serve as markers for PA-related autoimmunity.

Keywords

Autoimmunity Procainamide Nitroprocainamide Drug-related lupus

Get full access to this article

View all access options for this article.

References

Hess EV , Mongey A-B. Drug-related lupus: the same or different. In: Lahita RG , ed. Systemic Lupus Erythematosus , 2nd edition. New York: Churchill Livingstone, 1992: 893-904.

Adams LE , Hess EV Drug-related lupus. Incidence, mechanisms and clinical implications. Drug Safety 1991; 6: 431-49.

Rubin RL

Drug-induced lupus. Clin Asp

Autoimmunity 1988; 2:16-29.

Rubin RL Autoimmune reaction induced by procainamide and hydralazine. In: Kammuller ME , Bloksma N , Seinen W , eds. Autoimmunity and Toxicology . Amsterdam: Elsevier, 1989: 119-50.

Mongey A-B. , Donovan-Brand RJ , Thomas TJ , Adams LE , Hess EV Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992; 35: 219-23.

Fielder Ahl , Walport MJ , Batchelor JR et al. Family study of the major histocompatibility complex in patients with SLE. Importance of null alleles of C4A and C4B in determining susceptibility . Br Med J 1983 ; 286: 425-8.

Howard PF , Hochberg MC , Bias WB , Arnett FC , McLean RH Relationship between C4 null genes, HLA-D region antigens and genetic susceptibility to systemic lupus erythematosus in Caucasians and Black Americans . Am J Med 1986; 81: 187-93.

Welch TR , Beischel LS , Balakrishnan K. , Quinlan M. , West CD Major histocompatibility complex extended haplotypes in systemic lupus erythematosus . Disease Markers 1988; 6: 247-55.

McDermott M. , McDevitt HO The immunogenetics of rheumatic disease. Bull Rheum Dis 1988; 38: 1-10.

10.

Schur PH , Marcus-Bagley D. , Awdeh Z. , Yunis EJ , Alper CA The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus . Arthritis Rheum 1990; 33: 985-92.

11.

Fronek Z. , Timmerman LA , McDevitt HO A rare HLA-DQB allele sequenced from patients with systemic lupus erythematosus . Human Immunol 1991; 30: 77-84.

12.

Petranyi GG Susceptibility to autoimmune disease: a multigenic viewpoint. Immunol Today 1992; 13: A19-A20.

13.

Batchelor JR , Welsh KI , Tinoco RM et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility . Lancet 1984; i: 1102-9.

14.

Sim E. , Gill EW Drugs that induce systemic lupus erythematosus inhibit complement component C4. Lancet 1984; ii: 422-4.

15.

Russell GI , Bing RF , Jones Jag , Thurston H. , Swales JD Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype. Quart J Med 1987; 65: 845-52.

16.

Speirs C. , Fielder Ahl , Chapel H. , Davey NJ , Batchelor JR Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1989; i: 922-4.

17.

Sim E. , Stanley L. , Gill EM , Jones A. Metabolites of procainamide and practolol inhibit complement components of C3 and C4. Biochem J 1988; 251: 323-6.

18.

Sim E. Drug-induced immune complex disease. Biochem Soc Trans 1991; 19: 164-70.

19.

Woosley RL , Drayer DE , Reindenberg MD , Nies AS , Carr K. , Oats JA Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157-79.

20.

Sonnhag C. , Karlsson E. , Hed J. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand 1979; 206: 245-51.

21.

Litwin A. , Adams LE , Zimmer H. , Hess EV Immunologic effects of hydralazine in hypertensive patients. Arthritis Rheum 1981; 24: 1074-8.

22.

Roberts SM , Adams LE , Donovan-Brand R. et al. Procainamide hydroxylamine lymphocyte toxicity. 1. Evidence for participation by hemoglobin. Int J Immunopharmacol 1989; 11: 419-27.

23.

Wheeler JF , Lunte CE , Heineman WR , Adams LE , Hess EV Electrochemical determination of N-oxidized procainamide metabolites and functional assessment of effects on murine cells in vitro. Proc Soc Exp Biol Med 1988; 188: 381-6.

24.

Adams LE , Sanders CE Jr , Budinsky RA , Donovan-Brand R. , Roberts SM , Hess EV Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus. J Lab Clin Med 1989; 113: 482-92.

25.

Wheeler JF , Lunte CE , Zimmer H. , Heineman WR Electrochemical investigations of immunologically reactive procainamide metabolites . J Pharmac Biomed Anal 1990; 8: 143-50.

26.

Adams LE , Roberts SM , Carter JM et al. Effects of procainamide hydroxylamine on generation of reactive oxygen species by macrophages and production of cytokines. Int J Immunopharmacol 1990; 12: 809-19.

27.

Wheeler JF , Adams LE , Mongey A-B. , Roberts SM , Heineman WR , Hess EV Determination of metabolically derived nitroprocainamide in the urine of procainamide-dosed humans and rats by liquid chromatography with electrochemical detection. Drug Metabol Disposit 1991; 19: 691-5.

28.

Dinarello CA Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol 1991 ; 3: 941-8.

29.

Phair JP , Kauffman CA , Bjornson A. , Galiagher J. , Adams LE , Hess EV Host defenses in the aged: evaluation of competence in the inflammatory and immune responses. J Infect Dis 1978; 138: 67-73.

30.

Adams LE , Grant KD , Donovan RJ , Hess EV Comparative clinical and serologic study of antibodies in sera of rheumatic disease patients. Lab Med 1982; 13: 368-73.

31.

Spencer-Green G. , Kelley L. , Adams LE , Donovan-Brand R. , Hess EV

Polynucleotide antibodies in connective tissue disease: viral markers or disease mediators?

J Lab Clin Med 1986; 107: 159-65.

32.

Fritzler MJ , Tan EM Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J Clin Invest 1978; 62: 560-8.

33.

Portanova JP , Arndt RE , Tan EM , Kotzin BL Antihistone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions . J Immunol 1987; 138: 446-51.

34.

Totoritis MC , Tan EM , McNally EM , Rubin RL Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988; 318: 1431-6.

35.

Thomas TJ , Baarsch MJ , Messner RP Immunological detection of B-DNA to Z-DNA transition of polynucleotides by immobilization of the DNA on a solid support. Anal Biochem 1988; 1681: 358-66.

36.

Adams LE , Spencer-Green G. , Donovan-Brand R. et al. Comparison of four rheumatoid factor assays. Clin Lab Sci 1988; 1: 362-5.

37.

Reidenberg MM , Drayer DE , Levy M. , Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Therapeut 1975; 17: 722-30.

38.

Rocco RM , Abbott DC , Glese RW , Larger BL Analysis for procainamide and N-actyl procainamide in plasma or serum by high-performance liquid chromatography. Clin Chem 1977; 23: 705-8.

39.

Roberts SM , Budinsky RA , Adams LE , Litwin A. , Hess EV Procainamide acetylation in strains of rat and mouse. Drug Disposit 1985; 13: 517-9.

40.

Hopkins KA Basic microlymphocytotoxicity test. In: Zachary AA , Teresi GA , eds. American Society for Histocompatibility and Immunogenetics, Lenexa, Kansas: 1990: 195-205.

41.

Tsuji K, Aizawa M, Sasazuki T, eds. 11th International Histocompatibility Workshop. Data Analysis Book II. 1991: 10-1.

42.

Bias WB , Hochbery MC , McLean RH , Machan C. Joint report: systemic lupus erythematosus. In: Tsuji K, Aizawa M, Sagazuki T, eds. HLA 1991, Vol 1 Proceedings of the 11th Histocompatibility Workshop and Conference. Oxford: Oxford Science Publications, 1992: 740-5.

43.

Mongey A-B. , Balakrishnan K. , Ball E. , Brand R. , Hess EV , Adams LE Major histocompatibility complex (MHC) antigens and complement allotypes in patients receiving chronic procainamide (PA) treatment . Lupus 1992; 1 (Suppl 1): 32 (abstract).

44.

Alper CA , Awdeh ZL , Raum DD , Yunis EJ Extended major histocompatibility complex haplotypes in man: role of alleles analogous to murine T mutants. Clin Immunopath 1982; 24: 266-85.

45.

Hogan MM , Vogel SM Measurement of tumor necrosis factor alpha and beta. In: Coligan JE , Kruisbeek AM , Margulies DH , Shevach EM , Strober W , eds. Current Protocols in Immunology. New York : John Wiley & Sons, 1991: 6.10.1-6.10.5.

46.

Woolf B.

On estimating the relationship between blood group and disease. Ann

Human Genet 1955; 19: 215-53.

47.

Sell S. Immune tolerance and autoimmunity. In: Sell S , ed. Immunology, Immunopathology and Immunity, 4th edition. New York: Elsevier, 1987: 235-55.

48.

Lafer EM , Valler PC , Moller A. , Nordheim A. , Schur PH Z-DNA-specific antibodies in human systemic lupus erythematosus. J Clin Invest 1983; 71: 314-21.

49.

Thomas TJ , Seibold JR , Adams LE , Hess EV Role of left-handed Z-DNA in the production of autoantibodies in hydralazine-related lupus. Amer Fed Clin Res 1992; 40: 361A (abstract).

50.

Thomas TJ , Seibold JR , Adams LE , Hess EV Hydralazine induces Z-DNA conformation in a polynucleotide and elicits anti Z-DNA antibodies in treated patients. Biochem J 1993 (in press).

51.

Wheeler JF Electrochemical characterization, reaction studies and the metabolic disposition of N-oxidized metabolites of procainamide. Dissertation for Doctor of Philosophy . University of Cincinnati, 1990: 78-122.

52.

Broudy VC , Harlan JM , Adamson JW Disparate effects of tumor necrosis factor-α/cachectin and tumor necrosis factor-β/ lymphotoxin on hematopoietic growth factor production and neutrophil molecule expression by cultured human endothelial cells. J Immunol 1987; 138: 4298-302.

53.

Kunkel S. , Remick DG , Strieter RM , Larrick JM Mechanisms that regulate the production and effects of tumor necrosis factor-α . Crit Rev Immunol 1989; 9: 93-113.

54.

Stemme S. , Fager G. , Hansson GK MHC class II antigen expression in human vascular smooth muscle cells is induced by interferon-gamma and modulated by tumor necrosis factor and lymphotoxin . Immunology 1990; 69: 243-9.